Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Subbiah

Showing results (451-460 of 487) with videos related to

Pageof 49
Sort By:
BMJ Oncology|January 31, 2025
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancerChad Tang, Genevieve P Hartley, Coline Couillault, et al.
Thyroid : Official Journal of the American Thyroid Association|November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW StudyVivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
Cancer Discovery|April 17, 2018
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven CancersVivek Subbiah, Justin F Gainor, Rami Rahal, et al.
The Lancet. Diabetes & Endocrinology|June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 studyVivek Subbiah, Mimi I Hu, Lori J Wirth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Phase I Study of P-cadherin-targeted Radioimmunotherapy with <sup>90</sup>Y-FF-21101 Monoclonal Antibody in Solid TumorsVivek Subbiah, William Erwin, Osama Mawlawi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin LymphomaFilip Janku, Haeseong Park, S Greg Call, et al.
Cancer|November 2, 2018
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignanciesMinny Bhatty, Shumei Kato, Sarina A Piha-Paul, et al.
Future Oncology (London, England)|November 2, 2023
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW studyFrank Griesinger, Giuseppe Curigliano, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2021
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid MalignanciesAparna Hegde, Priyamvada Jayaprakash, Coline A Couillault, et al.
JCO Oncology Practice|October 7, 2024
Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of PracticeNazli Dizman, Ziad Bakouny, Tarek Haykal, et al.
Pageof 49

Showing results (451-460 of 487) with videos related to

Sort By:
Pageof 49
BMJ Oncology|January 31, 2025
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancerChad Tang, Genevieve P Hartley, Coline Couillault, et al.
Thyroid : Official Journal of the American Thyroid Association|November 27, 2023
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW StudyVivek Subbiah, Mimi I Hu, Aaron S Mansfield, et al.
Cancer Discovery|April 17, 2018
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven CancersVivek Subbiah, Justin F Gainor, Rami Rahal, et al.
The Lancet. Diabetes & Endocrinology|June 12, 2021
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 studyVivek Subbiah, Mimi I Hu, Lori J Wirth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2020
Phase I Study of P-cadherin-targeted Radioimmunotherapy with <sup>90</sup>Y-FF-21101 Monoclonal Antibody in Solid TumorsVivek Subbiah, William Erwin, Osama Mawlawi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin LymphomaFilip Janku, Haeseong Park, S Greg Call, et al.
Cancer|November 2, 2018
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignanciesMinny Bhatty, Shumei Kato, Sarina A Piha-Paul, et al.
Future Oncology (London, England)|November 2, 2023
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW studyFrank Griesinger, Giuseppe Curigliano, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2021
A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid MalignanciesAparna Hegde, Priyamvada Jayaprakash, Coline A Couillault, et al.
JCO Oncology Practice|October 7, 2024
Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of PracticeNazli Dizman, Ziad Bakouny, Tarek Haykal, et al.
Pageof 49